TP53 and neoplasm: Each entry outlines the cancer indication, ClinicalTrials.gov identifier, development phase, and a short note describing the mechanism or distinguishing features (e.g., p53-stabilizing CPP p28, antigen-loaded DC exosomes, tumor-lysate–pulsed DC vaccines, MSI-targeted immunotherapy, and the tumor-penetrating peptide LSTA1 that improves chemotherapeutic delivery).